In conversation with...

Alexandra Durr on riluzole in patients with spinocerebellar ataxia type 2

February 22, 2022 The Lancet Neurology
In conversation with...
Alexandra Durr on riluzole in patients with spinocerebellar ataxia type 2
Show Notes

Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of The Lancet Neurology.

Read the full article:
Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL)